68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · Dec 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called 68Ga-NK224 PET/CT, which helps doctors see a specific protein called PD-L1 in tumors. PD-L1 is important because it can influence how cancer cells interact with the immune system. The goal of the trial is to find out if this imaging method is useful for checking PD-L1 levels in patients with different types of cancer, especially compared to traditional testing methods done on tumor samples.

To participate in this trial, you need to be an adult (18 years or older) with a newly diagnosed or previously treated cancer, and you must be scheduled for a 68Ga-NK224 PET/CT scan. The study is open to all genders, and it is currently recruiting participants. If you join, you will undergo the PET/CT scan, and you will need to provide consent for your participation. It’s important to note that people with non-cancerous lesions, those who are pregnant, or anyone unable to give consent cannot take part in the study. This trial aims to gather valuable information that could improve how doctors evaluate and treat cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) adult patients (aged 18 years or order);
• • (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
• • (iii) patients who had scheduled 68Ga-NK224 PET/CT scans;
• • (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) patients with non-malignant lesions;
• • (ii) patients with pregnancy;
• • (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.